

Approxima secured a € 7.3M Series A financing round in the first closing to support advancement of a percutaneous right ventricular reshaping technology to treat patients with tricuspid valve regurgitation.

- **The financing round was co-led by ENEA Tech e Biomedical and Panakès Partners and the round remains open for subscription for additional co-investors**
- **The Series A funding will be deployed in preclinical verification, first-in-man clinical trial and US Early Feasibility Study**

Milan, Italy, February 20, 2025 – **Approxima Srl** announced today the **first closing** of a **Series A financing round securing € 7.3M**. The round was co-lead by ENEA Tech e Biomedical and Panakès Partners with strong continued support from current shareholders **Club degli Investitori** through **Simon Fiduciaria** and other **business angels**. The round remains open for subscription from other co-investors in the coming months. Concurrent with the financing, Chiara Vieceli, international industry expert in the cardiovascular sector, has joined as a member of the Board of Directors and further expansion of the Board is underway.

“I am deeply honored and grateful to have been appointed as a member of the Board of Directors. It is truly exciting to be part of a team dedicated to transforming the lives of patients with tricuspid valve regurgitation through innovative therapies. Together, we are pioneering a solution that holds the potential to restore the physiological function of the tricuspid valve and make a profound impact on patient outcomes. I look forward to contributing to the success and vision of Approxima as we work towards this transformative goal” commented Chiara Vieceli.

The funds raised in the new financing will be deployed to further advance the technology through conclusive pre-clinical verifications and pilot clinical trials.

Approxima is a MedTech startup, developing a percutaneous right ventricular reshaping technology to treat patients with tricuspid regurgitation (TR). This technology is being developed to offer a transformative approach to treating patients with TR by addressing its underlying cause — ventricular dilation - restoring thus the tricuspid valve function under a straightforward and efficient percutaneous implantation procedure. Its impact extends beyond the valve itself, improving also the right ventricle performance while maintaining all bailout options feasible, including native valve repair or valve replacement.

“During last two years our team has achieved significant technological advancements and provided robust pre-preclinical evidence. We are thrilled to have closed this major round of financing backed by continuous support from our current shareholders and a new investor who shares our vision. This milestone enables us to take this next significant step of executing pilot clinical studies.” commented Michal Jaworek, CEO and Co-founder of Approxima. *“There is an urgent need for new therapeutic solutions to address the growing clinical need posed by tricuspid valve regurgitation. In Approxima, we are developing an innovative technology that holds the promise of bridging this critical gap and improving patient outcomes. The secured funding will play a pivotal role in accelerating patient access to this therapy.”* added Dr. Paolo Denti, CMO of Approxima.

“We support the Company since its inception and we keep doing it as we truly believe in this new and well differentiated approach to offer a flexible therapeutic option to both clinicians and patients.” Barbara Castellano, Partner at Panakès Partners.

“This investment represents a significant step forward in precision medicine innovation. Approxima has developed a unique solution for the treatment of tricuspid insufficiency, a complex condition for which current therapeutic options have significant limitations. Our support for this groundbreaking technology consolidates our commitment to promoting advanced and personalized solutions that not only improve patients’ quality of life but also strengthen the national healthcare system by fostering the development of cutting-edge medical devices. This investment is a concrete demonstration of how the synergy between research, technology, and capital can generate a positive and long-lasting impact on the country’s healthcare system.” Maria Cristina Porta, General Manager of ENEA Tech e Biomedical.

“The secured funding will expedite patient access to Approxima’s unique and transformative solution which addresses directly the root cause of the disease. This technology is strategically positioned among the emerging tricuspid treatments, making it a strong fit for the portfolios of key players in the structural heart sector.” commented Umberto Pasquali, Chairman of the Board.

About tricuspid regurgitation

Tricuspid regurgitation (TR) significantly impacts quality of life and survival, especially in those over 60, mostly women, with a 36% one-year mortality rate. It causes frequent hospitalizations and burdens healthcare systems. With over 250,000 new cases annually in Europe and the U.S., numbers are rising due to aging populations. TR often results from conditions like left-sided valvular diseases, pulmonary hypertension and atrial fibrillation, causing annular and ventricular dilation. If left untreated, it leads to ventricular dysfunction and failure. Due to high surgical risks, most patients rely on limited medical therapy, highlighting the urgent need for effective minimally-invasive treatments.

About Approxima

Approxima was founded in 2020 by biomedical engineers M. Jaworek, E. Maroncelli, R. Vismara, G.B. Fiore and F. Lucherini as a spin-off from Politecnico di Milano. Approxima aspires to provide a transformative therapeutic solution for patients with tricuspid valve regurgitation based on the approach of ventricular reshaping which can restore physiological functioning of the tricuspid valve. The device is intended to be implanted into the heart of a patient via totally percutaneous and straightforward beating-heart procedure. The company headquarter is located in Milan, Italy.

<https://www.approximamedical.com/>

About Panakès Partners

Panakès Partners is the leading Italian venture capital firm in the Life Sciences sector, with the ultimate goal of providing a better life to people all around the world, by providing both financial and business support to build the next generation of game-changing technology companies in the field of Life Sciences. Panakès invests in ambitious start-ups and SMEs with innovative products globally, with a focus on Europe and Israel.

<http://www.panakes.it/>

About ENEA Tech e Biomedical

Fondazione ENEA Tech e Biomedical is a private foundation supervised by Ministry of Enterprises and Made in Italy. The mission of the Foundation is to promote investments and initiatives in scientific research, economic development and technology transfer to support Italian start-ups and innovative SMEs that operate in green and circular economy, information technology, agritech and deep tech. The Foundation also supports economic development of the Italian biomedical sector through initiatives aiming at connecting basic and preclinical research to clinical trial and production stages, creating highly specialized hubs, to improve the overall competitiveness and attractiveness towards investments, the ability to face public health emergencies. To achieve its purposes, Fondazione ENEA Tech e Biomedical manages the Technology Transfer Fund and the Biomedical Research and Industrial Development Fund.

<https://www.eneatechbiomedical.it/en/>